Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.01
- Piotroski Score 3.00
- Grade Buy
- Symbol (ARAY)
- Company Accuray Incorporated
- Price $1.80
- Changes Percentage (2.86%)
- Change $0.05
- Day Low $1.76
- Day High $1.81
- Year High $3.10
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.22
- Trailing P/E Ratio -8.09
- Forward P/E Ratio -8.09
- P/E Growth -8.09
- Net Income $-15,545,000
Income Statement
Quarterly
Annual
Latest News of ARAY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mansaray's TD in 2nd overtime gives Valparaiso 31-23 win
Valparaiso defeated Roosevelt 31-23 in double overtime with Michael Mansaray's 16-yard run. Mansaray scored two touchdowns, while Roosevelt's Budke and Nixon had strong performances in the game....
By AP NEWS | 1 week ago -
Jocelyn Nungaray murder: Houston prosecutors seek ICE, CBP records on illegal accused of child killing
Johan Jose Martinez Rangel and Franklin Pena, illegal immigrants charged with the capital murder of 12-year-old Jocelyn Nungaray in Houston, appeared in court. Prosecutors requested access to Rangel's...
By Fox News | 2 weeks ago -
How Chelsea and Saudi target Victor Osimhen ended up at Galatasaray | Ed Aarons
Victor Osimhen's unexpected loan move to Galatasaray followed a whirlwind weekend, with Napoli's open door for a potential January move. The Nigerian striker's transfer saga involved rejected offers, ...
By The Guardian | 3 weeks ago
